Even though a powerful immune signal called IFN-γ is made during Pneumocystis infection, the body can still get rid of the fungus without it — but without IFN-γ, the lungs get much more inflamed and...
Claim Context
IFN-γ, a key cytokine of Th1 cells, is not essential for clearing Pneumocystis in mice, as mice lacking IFN-γ or its receptor clear the infection normally, but it plays a critical role in suppressing excessive lung inflammation during infection.
“However, IFN-γ is not essential for Pneumocystis clearance, as mice deficient in IFN-γ or its receptor exhibit unimpaired fungal clearance... In contrast, IFN-γ plays an important regulatory role in controlling inflammation.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether blocking IFN-γ in humans with PCP worsens inflammation without affecting fungal clearance.
A phase II double-blind RCT of 60 immunocompromised patients with PCP, randomized to receive anti-IFN-γ monoclonal antibody (5 mg/kg) or placebo for 14 days, with primary outcomes: BAL fungal burden (qPCR) and lung injury biomarkers (SP-D, albumin, IL-6).
Whether serum or BAL IFN-γ levels correlate with inflammation severity but not fungal burden in human PCP.
A prospective cohort of 100 immunocompromised patients with PCP, measuring serial IFN-γ levels in BAL and serum alongside clinical inflammation markers (CRP, oxygenation index, radiographic infiltrate score) and fungal burden (qPCR).
Whether patients with inherited IFN-γ or IFN-γR deficiencies develop PCP more frequently than expected.
A matched case-control study of 30 patients with inherited IFN-γ/IFN-γR mutations and 60 controls, assessing PCP incidence, severity, and outcomes in mutation carriers.
Whether IFN-γ levels are elevated in the lungs of PCP patients compared to those with other pneumonias.
A cross-sectional analysis of BAL fluid from 80 patients: 30 with PCP, 25 with bacterial pneumonia, 25 with viral pneumonia, measuring IFN-γ, IL-17, and TNF-α levels.
Clinical course of PCP in patients with known IFN-γ pathway defects.
A case series of 5 patients with IFN-γR1 mutations who develop PCP, documenting clinical presentation, inflammatory markers, and response to therapy.